We're so glad you're here! This site is to help anyone diagnosed with Medullary Thyroid Cancer and their caregivers find valuable information and support. If you'd like to connect with others with MTC, please consider joining our very active Facebook Group. You don't have to go through this alone!
If you don't yet have a copy, please download the American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, aka "The Guidelines." This is the MTC Bible. Read it and know it and it will help you and your doctor ensure you get the proper treatment.
Lastly, please consider looking into being seen by an MTC expert. We do our best to keep a running list of what we call "Centers of Excellence." These are doctors and facilities that are properly trained and experienced enough to treat MTC patients. It's one of the most important decisions you can make on your journey.
"Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high ..."
"... RET inhibitor, lunbotinib fumarate (A400/EP0031, ), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung ..."
"FDA granted traditional approval to Retevmo (selpercatinib) for adult and pediatric patients two years of age and older with advanced or metastatic ..."
"... selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors. FDA granted accelerated approval to selpercatinib (Retevmo, Eli ..."
"These cancers are called familial medullary thyroid carcinoma. They can start in childhood or early adulthood and spread early. Some people who have ..."
This website is intended for educational purposes only. It is not intended, nor should it be interpreted, as medical advice or instructions of any kind. Readers are advised to consult their own medical doctor(s) for all matters involving their health and medical care.